These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 24604234)

  • 1. Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age.
    Pohl O; Bestel E; Gotteland JP
    Reprod Sci; 2014 Oct; 21(10):1256-65. PubMed ID: 24604234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
    Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
    Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
    Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
    Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
    Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
    Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
    Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate.
    Singh H; Uniyal JP; Jha P; Takker D; Murguesan K; Hingorani V; Laumas KR
    Acta Endocrinol (Copenh); 1982 Feb; 99(2):302-8. PubMed ID: 7058686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief.
    Panay N; Ylikorkala O; Archer DF; Gut R; Lang E
    Climacteric; 2007 Apr; 10(2):120-31. PubMed ID: 17453860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives.
    Fels H; Steward R; Melamed A; Granat A; Stanczyk FZ; Mishell DR
    Contraception; 2013 Jun; 87(6):732-7. PubMed ID: 23352800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction.
    Nijland EA; Nathorst-Böös J; Palacios S; van de Weijer PW; Davis S; Stathopoulos VM; Birkhaeuser MH; von Mauw E; Mulder RJ; Schultz WC;
    Climacteric; 2009 Apr; 12(2):114-21. PubMed ID: 19177255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model.
    Colette S; Defrère S; Lousse JC; Van Langendonckt A; Gotteland JP; Loumaye E; Donnez J
    Hum Reprod; 2011 Jun; 26(6):1362-70. PubMed ID: 21441545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
    Nakajima ST; Archer DF; Ellman H
    Contraception; 2007 Jan; 75(1):16-22. PubMed ID: 17161118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of norethisterone acetate and estradiol on the serotonin metabolism of postmenopausal women.
    Mueck AO; Seeger H; Kasspohl-Butz S; Teichmann AT; Lippert TH
    Horm Metab Res; 1997 Feb; 29(2):80-3. PubMed ID: 9105905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
    Junge W; El-Samalouti V; Gerlinger C; Schaefers M
    Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate.
    Odmark IS; Jonsson B; Bäckström T
    Am J Obstet Gynecol; 2001 May; 184(6):1131-8. PubMed ID: 11349178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfatase inhibitors: a patent review.
    Williams SJ
    Expert Opin Ther Pat; 2013 Jan; 23(1):79-98. PubMed ID: 23136854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
    Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.